1.07

7.00% 0.07

After Hours: 1.05 -0.02 -1.87%

Tvardi Therapeutics Inc (TVRD)

Overview News Price History Option Chain Financials Discussions Forecast

Tvardi Therapeutics Inc stock is traded at $1.07, with a volume of 93,136. It is up +7.00% in the last 24 hours and down -39.20% over the past month. Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Previous Close:

$1.00

Open:

$1.03

24h Volume:

93,136

Relative Volume:

0.61

Market Cap:

$14.27M

Revenue:

$2.57M

Net Income/Loss:

$-15.44M

P/E Ratio:

-0.3458

EPS:

-3.0946

Net Cash Flow:

$-24.67M

1W Performance:

-0.93%

1M Performance:

-39.20%

6M Performance:

-69.16%

1Y Performance:

-83.89%

1-Day Range:

$1.00

$1.07

1-Week Range:

$0.97

$1.09

52-Week Range:

$0.93

$7.23

Tvardi Therapeutics Inc Stock (TVRD) Company Profile

Name

Tvardi Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(713) 489-8654

Address

3 SUGAR CREEK CTR. BLVD., SUGAR LAND

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

TVRD's Discussions on Twitter

Compare TVRD vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVRD Tvardi Therapeutics Inc	1.07	14.27M	2.57M	-15.44M	-24.67M	-3.0946
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-26	Upgrade	Piper Sandler	Neutral → Overweight
Jul-08-26	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-08-26	Initiated	H.C. Wainwright	Buy
Apr-20-26	Downgrade	Barclays	Equal Weight → Underweight
Oct-14-25	Downgrade	Barclays	Overweight → Equal Weight
Oct-14-25	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-25	Initiated	Barclays	Overweight
Oct-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-14-25	Initiated	Raymond James	Outperform
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight
Jun-12-25	Initiated	Piper Sandler	Overweight
May-21-25	Initiated	Oppenheimer	Outperform
May-15-25	Initiated	BTIG Research	Buy
Jun-13-24	Downgrade	Canaccord Genuity	Buy → Hold
Jun-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-13-24	Downgrade	Needham	Buy → Hold
Jun-13-24	Downgrade	Stifel	Buy → Hold
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy

View All

Tvardi Therapeutics Inc Stock (TVRD) Latest News

Oct 14, 2026

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference - GlobeNewswire Inc.

Oct 14, 2026

Sep 08, 2026

Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com

Sep 08, 2026

Lucid Capital Markets initiates Tvardi stock with buy rating By Investing.com - Investing.com Nigeria

Sep 08, 2026

Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com India

Sep 08, 2026

Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com

Sep 08, 2026

Aug 28, 2026

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Barchart.com

Aug 28, 2026

Aug 26, 2026

Tvardi Therapeutics to Participate in Upcoming Investor Events - Barchart.com

Aug 26, 2026

Tvardi (TVRD) Q1 2026 Results: The EPS Result Is Above Expectation in the Latest Reading; After Earnings: Shares Close 2.25% Higher in Latest TradingEarnings Whisper Number - vinanet.vn

Aug 26, 2026

Aug 21, 2026

Tvardi Therapeutics (TVRD) Receives a Hold from Cantor Fitzgerald - The Globe and Mail

Aug 21, 2026

Aug 20, 2026

Tvardi (TVRD) Shares: Finishes 2.66% Down at $1.83 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.74 to $1.92 on the DayFlat Correction - vinanet.vn

Aug 20, 2026

BTIG Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 20, 2026

Aug 19, 2026